vs
Side-by-side financial comparison of CORVEL CORP (CRVL) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
CORVEL CORP is the larger business by last-quarter revenue ($235.6M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 3.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.6%).
Corvel Corp is a U.S.-headquartered provider of integrated workers’ compensation, healthcare management, and risk mitigation solutions. It serves insurance carriers, self-insured employers, and public sector clients, delivering services to control healthcare costs, improve care outcomes, and optimize administrative operations.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CRVL vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $235.6M | $168.4M |
| Net Profit | $24.2M | — |
| Gross Margin | 23.3% | — |
| Operating Margin | 13.7% | 50.6% |
| Net Margin | 10.3% | — |
| Revenue YoY | 3.4% | 143.7% |
| Net Profit YoY | 1.7% | — |
| EPS (diluted) | $0.47 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $235.6M | $168.4M | ||
| Q3 25 | $239.6M | $87.3M | ||
| Q2 25 | $234.7M | $82.4M | ||
| Q1 25 | $231.5M | $65.0M | ||
| Q4 24 | $228.0M | $69.1M | ||
| Q3 24 | $224.4M | $51.6M | ||
| Q2 24 | $211.7M | $73.8M | ||
| Q1 24 | $207.2M | $137.7M |
| Q4 25 | $24.2M | — | ||
| Q3 25 | $27.9M | $-31.3M | ||
| Q2 25 | $27.2M | $-12.7M | ||
| Q1 25 | $26.4M | $-40.5M | ||
| Q4 24 | $23.8M | — | ||
| Q3 24 | $23.4M | $-29.5M | ||
| Q2 24 | $21.6M | $-61.9M | ||
| Q1 24 | $19.5M | $61.0M |
| Q4 25 | 23.3% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 25.0% | — | ||
| Q4 24 | 23.2% | — | ||
| Q3 24 | 22.6% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 20.9% | — |
| Q4 25 | 13.7% | 50.6% | ||
| Q3 25 | 15.0% | -11.4% | ||
| Q2 25 | 15.0% | 8.6% | ||
| Q1 25 | 14.4% | -34.0% | ||
| Q4 24 | 13.5% | -6.4% | ||
| Q3 24 | 12.8% | -31.0% | ||
| Q2 24 | 13.2% | 3.5% | ||
| Q1 24 | 10.9% | 52.5% |
| Q4 25 | 10.3% | — | ||
| Q3 25 | 11.6% | -35.9% | ||
| Q2 25 | 11.6% | -15.4% | ||
| Q1 25 | 11.4% | -62.2% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 10.4% | -57.2% | ||
| Q2 24 | 10.2% | -83.9% | ||
| Q1 24 | 9.4% | 44.3% |
| Q4 25 | $0.47 | $0.32 | ||
| Q3 25 | $0.54 | $-0.16 | ||
| Q2 25 | $0.52 | $-0.06 | ||
| Q1 25 | $-1.23 | $-0.21 | ||
| Q4 24 | $0.46 | $-0.14 | ||
| Q3 24 | $1.35 | $-0.15 | ||
| Q2 24 | $1.25 | $-0.33 | ||
| Q1 24 | $1.12 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $230.0M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $375.7M | $-302.0M |
| Total Assets | $644.8M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0M | $167.9M | ||
| Q3 25 | $207.5M | $92.4M | ||
| Q2 25 | $202.0M | $86.1M | ||
| Q1 25 | $170.6M | $114.6M | ||
| Q4 24 | $162.9M | $144.8M | ||
| Q3 24 | $138.3M | $144.7M | ||
| Q2 24 | $131.9M | $189.3M | ||
| Q1 24 | $105.6M | $226.6M |
| Q4 25 | $375.7M | $-302.0M | ||
| Q3 25 | $362.8M | $-451.4M | ||
| Q2 25 | $342.5M | $-433.5M | ||
| Q1 25 | $322.0M | $-426.2M | ||
| Q4 24 | $300.9M | $-388.7M | ||
| Q3 24 | $282.8M | $-370.2M | ||
| Q2 24 | $263.9M | $-344.2M | ||
| Q1 24 | $247.6M | $-294.3M |
| Q4 25 | $644.8M | $465.9M | ||
| Q3 25 | $611.7M | $364.0M | ||
| Q2 25 | $597.4M | $347.1M | ||
| Q1 25 | $546.0M | $324.0M | ||
| Q4 24 | $538.8M | $343.8M | ||
| Q3 24 | $518.6M | $314.1M | ||
| Q2 24 | $486.2M | $352.3M | ||
| Q1 24 | $454.7M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.1M | $45.2M |
| Free Cash FlowOCF − Capex | $35.2M | — |
| FCF MarginFCF / Revenue | 14.9% | — |
| Capex IntensityCapex / Revenue | 4.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.91× | — |
| TTM Free Cash FlowTrailing 4 quarters | $104.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.1M | $45.2M | ||
| Q3 25 | $25.0M | $-4.3M | ||
| Q2 25 | $55.0M | $-31.4M | ||
| Q1 25 | $22.9M | $-22.6M | ||
| Q4 24 | $41.6M | $-35.0M | ||
| Q3 24 | $22.3M | $-35.3M | ||
| Q2 24 | $40.4M | $-7.2M | ||
| Q1 24 | $15.2M | $53.8M |
| Q4 25 | $35.2M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $39.5M | — | ||
| Q1 25 | $14.3M | — | ||
| Q4 24 | $32.1M | — | ||
| Q3 24 | $12.4M | $-35.5M | ||
| Q2 24 | $32.8M | $-7.3M | ||
| Q1 24 | $5.2M | $53.8M |
| Q4 25 | 14.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 6.2% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 5.5% | -68.7% | ||
| Q2 24 | 15.5% | -9.9% | ||
| Q1 24 | 2.5% | 39.0% |
| Q4 25 | 4.7% | 0.0% | ||
| Q3 25 | 4.1% | 0.0% | ||
| Q2 25 | 6.6% | 0.0% | ||
| Q1 25 | 3.7% | 0.0% | ||
| Q4 24 | 4.2% | 0.0% | ||
| Q3 24 | 4.4% | 0.3% | ||
| Q2 24 | 3.6% | 0.1% | ||
| Q1 24 | 4.8% | 0.1% |
| Q4 25 | 1.91× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 2.02× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 1.75× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 0.78× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRVL
| Patient Management Services | $146.1M | 62% |
| Network Solutions Services | $89.6M | 38% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
